Research Article

LncRNA-URHC Functions as ceRNA to Regulate DNAJB9 Expression by Competitively Binding to miR-5007-3p in Hepatocellular Carcinoma

Kunwei Niu, Shibin Qu, Xuan Zhang, Jimin Dai, Jianlin Wang, Ye Nie, Hong Zhang, Kaishan Tao, and Wenjie Song

Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, 127 Changle Road, Xi'an, Shaanxi 710032, China

Correspondence should be addressed to Kaishan Tao; taokaishan0686@163.com and Wenjie Song; surgeon2002@163.com

Received 24 August 2021; Accepted 14 September 2021; Published 7 October 2021

Academic Editor: Songwen Tan

Copyright © 2021 Kunwei Niu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Hepatocellular carcinoma (HCC) is often diagnosed at a late stage, when the prognosis is poor. The regulation of long noncoding RNAs (lncRNAs) plays a crucial role in HCC. However, the precise regulatory mechanisms of lncRNA signaling in HCC remain largely unknown. Our study aims to investigate the underlying mechanisms of lncRNA (upregulated in hepatocellular carcinoma) URHC in HCC. Objective. To study the in vivo and in vitro localization and biological effects of URHC on liver cancer cells. Through bioinformatics analysis, dual-luciferase reporter gene analysis and rescue experiments revealed the possible mechanism of URHC. Methods. RT-qPCR, fluorescence in situ hybridization (FISH) staining, EdU, colony formation, and tumor xenograft experiments were used to identify localized and biological effects of URHC on HCC cells in vitro and in vivo. The bioinformatics analysis, dual-luciferase reporter assay, and rescue experiments revealed the potential mechanism of URHC. Results. URHC silencing may inhibit the HCC cells’ proliferation in vitro and in vivo. We found that URHC was mainly localized in the cytoplasm. The expression of miR-5007-3p was negatively regulated by URHC. And miR-5007-3p could reverse the effect of URHC in HCC cells. The expression of DNAJB9 was negatively regulated by miR-5007-3p but positively regulated by URHC. These suggest URHC and miR-5007-3p have a regulatory role in the level of DNAJB9 in HCC cells. Conclusion. Together, our study elucidated the role of URHC as a miRNA sponge and shed new light on lncRNA-directed diagnostics and therapeutics in HCC.

1. Introduction

Hepatocellular carcinoma (HCC) is the most common type of liver tumor worldwide. It has become the second leading cause of cancer-related death in China [1, 2]. Tumor resection is currently the best treatment choice among the several therapeutic methods available. However, HCC is often diagnosed at a late stage when the rupture of HCC caused haemoperitoneum, which is with poor prognosis generally [3]. The extrahepatic metastases of HCC represent a poor prognostic factor. In particular, orbital metastasis rarely occurs [4]; and many patients die within 1 year after the detection of HCC [5]. Therefore, enhancing our understanding of the molecular mechanisms in HCC is essential for the development of effective treatment strategies. Recent experimental studies provide strong evidence that lncRNAs play an important role in cancer progression, and the abnormal expression of lncRNAs has been found in the HCC [6–9]. For example, lncRNA HOST2 can activate the JAK2-STAT3 signaling pathway and promote epithelial-mesenchymal transition, proliferation, invasion, and migration of HCC cells [9]. A lncRNA PVT1/miR-150/HIG2 axis regulates the proliferation, invasion, and balance of iron metabolism in HCC [10]. LncRNAs have been shown to function as miRNA sponges, which interact with miRNAs and play crucial roles in human carcinogenesis by modulating the expression of...
miRNA target genes [11–14]. These may contribute to the development of new effective therapeutic strategies to improve the prognosis of HCC patients.

Many aberrant expression patterns of IncRNAs have been found to be associated with human diseases, in particular, cancers [15–19]. They can regulate gene expression in cis or in trans by diverse mechanisms [20–22] and have been demonstrated to cause dysregulation of IncRNAs and impact on cellular functions such as cell proliferation, apoptosis, migration, invasion, tumorigenicity, and metastasis, by interacting with DNA, RNA, and proteins [23, 24]. By negatively regulating the expression of target genes, miRNAs play a significant role at the posttranscriptional level and participate in a large number of biological processes, including cell proliferation, cell cycle, apoptosis, and differentiation [25–29]. Recent studies have revealed that IncRNAs can function as competing endogenous RNAs (ceRNAs) to regulate the expression pattern and biological characteristics of miRNAs [30, 31].

In the present study, we investigated the biological effects of URHC overexpression on cell proliferation in HCC. Bioinformatics prediction and experimental analysis confirmed that URHC directly targeted miR-5007–3p to regulate its expression. Furthermore, mechanistic analysis revealed that URHC positively regulated DNAJB9 by sponging miR-5007–3p, indicating that it plays an oncogenic role in HCC pathogenesis. Together, these results suggest that the molecular mechanisms of URHC-miR-5007–3p-DNAJB9 axis are likely to be enriched in HCC.

2. Materials and Methods

2.1. Cell Culture and Transfection. The human HCC cell line Hep3B and 293T cells were purchased from ATCC. The normal human liver cell line MIHA was purchased from Yaji Biological (Shanghai, China). HCC cells Bel-7402 and Bel-7404 were obtained from Beina Biological (Beijing, China) in 2017. The SMMC-7721 was bought from Fenghui Biotechnologies Inc. (Hunan, China). MIHA, SMMC-7721, Bel-7402, and Bel-7404 cells were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS, Invitrogen). Hep3B and 293T cells were cultured in Dulbecco’s modified Eagle medium (DMEM, Invitrogen) containing 10% FBS. All cells were incubated in a humidified atmosphere of 5% CO₂ at 37°C. Dimethyl sulfoxide was purchased from Sigma-Aldrich (St. Louis, MO).

Scrambled siRNA of URHC (siRNA-Con) and URHC siRNAs were purchased from GenePharma (Shanghai, China). miR-5007–3p inhibitor, inhibitor negative control (NC inhibitor), miR-5007–3p mimic, and NC mimic were also purchased from GenePharma (Shanghai, China). Full-length URHC cDNA was subcloned into GV230 lentiviruses (Genechem, Shanghai, China) and infected into Bel-7404 and Hep3B cells to generate URHC-overexpressing cells. Lipofectamine 2000 Reagents (Invitrogen Co., USA) were used for cell transfections.

2.2. Human Tissue Samples. We obtained 26 pairs of primary HCC and adjacent nontumor tissues from patients undergoing surgery at Xijing Hospital, the Fourth Military Medical University; all diagnoses were based on a biopsy. These tissues were immediately frozen in liquid nitrogen after surgical resection. All patients provided written informed consent, and these studies were approved by the Ethics Review Committees of Xijing Hospital.

2.3. Reverse Transcription and Quantitative Real-Time PCR. Total RNA was prepared from the indicated cells using TRIzol reagent (Invitrogen) based on the manufacturer’s instructions. One microgram of total RNA was converted to cDNA using PrimeScript® RT Master Mix Perfect Real-Time (Takara, Inc). SYBR Premix Ex Taq II (Takara) was used based on the manufacturer’s instructions under the following conditions: 95°C for 2 min, 95°C for 15 s, and 60°C for 60 s for 40 cycles. miR-5007–3p expression levels were quantified using MicroRNA First-Strand Synthesis and miRNA Quantitation Kits including U6 control primer (Takara) based on the manufacturer’s instructions. The control experiments were analyzed based on the 2⁻ΔΔCt formula [32]. The primers used for RT-qPCR were as follows: β-actin; sense 5'-CTGGAACGGTGAAAGTGACA-3', and antisense 5'-CGGCCACATTGTGAACTTTG-3'; URHC; sense 5'-TGGTATGTGAGAGGAGAAAGGAAG-3', and antisense 5'-CACCAGGTCTGCAAATAGTGA-3'; DNAJB9; sense 5'-TAGGCACACACCACCATC-3', and antisense 5'-CTTTGGGAGGCCAAGGTAGG-3'; and miR-5007–3p 5'-CCATAGAACAACTCTAATA-3'. The internal control genes were β-actin for URHC, DNAJB9, and U6 snRNA for miR-5007–3p.

2.4. Fluorescence In Situ Hybridization. SMMC-7721 and Hep3B cells were plated to achieve 70% confluency for staining. Frozen sections of HCC tissues were treated with 4% DNase/RNase-free paraformaldehyde. After fixation, the sections were treated with Proteinase K (20 g/ml) for 5 min and then washed three times with phosphate-buffered saline (PBS). The cells were incubated with a prehybridization solution for 1 h at 37°C. Then, the prehybridization solution was removed, and the cells were covered with a URHC probe (8 ng/μl) hybridization solution overnight in a 37°C incubator. The slices were washed three times using Wash Buffer Solution. The cells were extensively washed three times using Wash Buffer Solution, counterstained with DAPI, and mounted with an antifade reagent (Invitrogen). The URHC probe for fluorescence in situ hybridization (FISH) was 5'-GFP-AGTACATACTCACACTACAGGCTGCA-GFP-3' (Servicebio, China). The mir-5007–3p probe for FISH was 5'-Cy3-ATTAGAGTTTGGTCTATGAT-Cy3-3' (Servicebio).

2.5. CCK-8 and Colony Formation Assays. The CCK-8 assay was used to assess HCC cell proliferation. HCC cells were seeded in a 96-well plate at a density of 2 × 10³ cells per well. Cell proliferation was measured at 24, 48, 72, and 96 h. CCK-8 solution (10 L) was added to each well, and incubated for 1 h at 37°C, in a 5% CO₂ incubator. After incubation, the optical density (OD) 450 value was read using an Epoch
Spectrophotometer (USA). Experiments were repeated at least three times.

The colony formation assay was performed to measure the capacity of cell proliferation. SMMC-7721 and Hep3B cells (300 cells/well) were seeded in a six-well plate and cultured for 10 days. Colonies were then fixed with methanol for 15 min and stained for 10 min with 0.5% crystal violet. Then, colonies were imaged with a phone and analyzed by ImageJ software. The assays were repeated at least three times.

2.6. 5-Ethynyl-2'-Deoxyuridine (EdU) Assay. Cell proliferation was also determined by the 5-ethyl-2'-deoxyuridine assay using an Apollo®488 EdU Kit (RIBOBIO, Guangzhou, China). The EdU assay was performed based on the manufacturer's instructions. The cells were then visualized under a fluorescence microscope (20×10). To assess cell proliferation, the ratio of EdU-stained cells (with red fluorescence) to Hoechst-stained cells (with blue fluorescence) was calculated. Experiments were repeated at least three times.

2.7. Luciferase Reporter Assay. The luciferase reporter assay was performed in 293T cells. The 293T cells were seeded in a six-well plate and cotransfected with luciferase reporter constructs encoding the wild-type 3'-UTR region of DNAJB9 or URHC (DNAJB9/URHC-WT-3'-UTR) or a mutated 3'-UTR region of DNAJB9 or URHC 3'-UTR region (DNAJB9/URHC-MUT-3'-UTR) (RIBOBIO, Guangzhou, P.R. China) and miR-5007-3p mimic or mi-NC using Lipofectamine 2000 (Invitrogen). After 48 h of incubation, the cells were washed with PBS and lysed with Passive Lysis Buffer (Promega). Firefly and Renilla luciferase activities were measured using the dual-luciferase reporter assay kit (Promega) based on the manufacturer’s protocol.

2.8. Western Blot Assay. Cells were lysed using RAPI buffer (Beytime, China). Total proteins were quantified using the BCA Protein Assay Kit (Beytime, China). Proteins were separated by 12% SDS-polyacrylamide gel electrophoresis and transferred to a polyvinylidene fluoride (PVDF) membranes (Milipore, Inc.). The membranes were washed three times for 10 mins with Tris-buffered saline-0.5% Tween 20 (TBS-T) and blocked with 5% nonfat milk-TBS-T at room temperature for 1 h. Subsequently, they were incubated with primary antibodies (anti-DNAJB9 (1:1000) and anti-GAPDH (1:1000) obtained from Abcam and Cell Signaling Technology, respectively) at 4°C overnight. Following incubation with corresponding secondary antibodies, the signals were detected with ECL Western Blotting Detection Reagents (Milipore, Inc.). GAPDH was used as an endogenous reference.

2.9. Immunohistochemical (IHC) Assay. DNAJB9 and Ki67 were detected in xenograft tumor specimens of nude mice, which were fixed with paraformaldehyde, embedded with paraffin, and cut into 4 μm sections. The subsequent steps accomplished with the biotin-streptavidin peroxidase method (SPlink Detection Kit, ZSGB-Bio, Beijing, China) were followed based on the manufacturer’s instructions. Briefly, paraffin-embedded samples were deparaffinized, dehydrated in a graded series of ethanol and blocked with endogenous peroxidase for 10 min, and incubated in goat serum for 30 min. The slides were incubated with the corresponding primary antibodies at 4°C overnight. Then, the slides were washed with PBS, incubated with biotinylated goat anti-rabbit IgG, and then incubated with horseradish peroxidase (HRP) conjugated streptomycin. Diaminobenzidine (ZSGB-Bio) was added to the slides for chromogenic reaction. The slides were observed with an optical microscope (Olympus, Tokyo, Japan).

2.10. In Vivo Proliferation Assay. Six-week-old male BALB/c nude mice were obtained from Vital River Laboratory Animal Technology Co. (Beijing, China). Animal studies were approved by the Institutional Animal Care and Use Committee of Fourth Military Medical University. The mice were housed in pathogen-free conditions. To further determine the antitumorigenesis potential of URHC in vivo, 7721 cells transfected with siRNA-NC and URHC-siRNA were inoculated into male nude mice. Mice were randomly divided into two groups with five mice in each group, but each group only included three tumors. siRNA-URHC and URHC-NC cells (1×10^6) were inoculated subcutaneously in the right flank of nude mice. Tumors were measured every 7 days, and tumor volumes were calculated. Five weeks after HCC cell inoculation, the mice were sacrificed, and the tumors were collected.

2.11. Statistical Analysis. All experimental data were reported as means ± experimental standard deviations (SD). Student’s t-test was used to determine the significance of the results (significance: * P < 0.05; ** P < 0.01; *** P < 0.001).

3. Results

3.1. URHC Promotes Cell Proliferation of HCC In Vitro and In Vivo. Previous data indicate that URHC expression is upregulated in HCC cell lines and tissues [33]. 7404 and Hep3B cells exhibited lower URHC expression than the 7721 and 7402 HCC cell lines (Figure 1(a)), so we selected 7404 and Hep3B cells to construct stable cell lines to overexpression URHC, and the transfection efficiency was detected by RT-qPCR (Figure 1(b)). The previous results of CCK-8 and EdU assays demonstrated that the down-regulated expression of URHC attenuated the proliferation of 7721 cells [32], whereas the overexpression of URHC enhanced 7404 and Hep3B cells proliferation by CCK-8 and colony formation assays (Figures 1(c) and 1(d)). Mice injected with siRNA-URHC 7721 cells showed a reduction in tumor volume and weight at the end of the experiment compared with the control groups (Figures 1(e)–1(g)). Moreover, IHC staining revealed that Ki67 (proliferation marker) expression was decreased in the siRNA-URHC xenograft tumor tissues (Figure 1(h)). These results suggest
Figure 1: Continued.
that URHC expression may play an important role in the cell proliferation of HCC in vitro and in vivo.

3.2. URHC Is Predominantly Localized in the Cell Cytoplasm. Since many lncRNA are not restricted to either the nuclear or cytoplasmic compartment [34, 35], but cellular location is known to dictate the function of lncRNAs. However, the subcellular location of URHC is unclear. A FISH assay was performed to identify the subcellular localization of URHC in 7721 cells, Hep3B cells, HCC tissues, and adjacent tissues. Moreover, cellular fractionation was performed to identify the subcellular localization of URHC in 7721 and Hep3B cells. The results confirmed that URHC was mainly localized in the cell cytoplasm (Figures 2(a)–2(c)).

3.3. URHC Can Function as ceRNA to Sponge miR-5007-3p. Increasing evidence has revealed that lncRNAs contain sequences that are complementary to miRNAs and that they can directly or indirectly regulate the expression and activity of miRNAs. The potential targets of URHC were predicted by the bioinformatics database (StarBase). We observed that several potential miRNAs had putative binding sites for URHC, such as miR-5007-3p, miR-4698, miR-559, and miR-3942-3p (Table 1). Compared with the other three potential miRNAs, the expression level of miR-5007-3p was the lowest in the URHC high expressing HCC cells and highest in the URHC low expressing HCC cells (Figures 3(a) and S1). Next, we measured the expression of miR-5007-3p in HCC tissues and normal tissues. As shown in the RT-qPCR results in Figure 3(b), the expression of miR-5007-3p was significantly downregulated in HCC tissues compared with that in the adjacent tissues. To confirm our prediction that miR-5007-3p targets URHC, we first measured the expression levels of miR-5007-3p in 7404, Hep3B, 7721, and 7402 cells that were transfected with over-URHC or siRNA-URHC, respectively, by RT-qPCR. The results showed that the expression of miR-5007-3p was decreased in the over-URHC group compared with the overcontrol group, whereas the expression of miR-5007-3p was increased in the siRNA-URHC group compared with the siRNA-control group (Figure 3(c)). Meanwhile, RT-qPCR analysis of resected tumor tissues demonstrated same results (Figure 3(d)). Additionally, we determined the location of URHC and miRNA-5007-3p in HCC tissues, normal tissues, and cell lines. The FISH results showed that URHC and miRNA-5007-3p were colocalized in the cell cytoplasm (Figure 3(e)). These results suggest that URHC may negatively regulate the expression of miR-5007-3p. Moreover, we confirmed the direct relationship between URHC and miR-5007-3p using a dual-luciferase reporter assay. Using the bioinformatic database, we predicted the potential miRNA binding sites in URHC, and the alignment of miR-5007-3p with the 3′-UTR of URHC was shown (Figure 3(f)). 293T cells were cotransfected with miRNAs and URHC (URHC-NC, URHC mutant). As shown in Figure 3(g), miR-5007-3p mimic transfection significantly decreased the luciferase activities of URHC compared with NC transfection, whereas there were no effects on the luciferase activities by miR-5007-3p mutant transfection. These results indicate that URHC directly targets miR-5007-3p to regulate its expression.

3.4. miR-5007-3p Reverses the Promoting Effect of URHC on Cell Growth. We next determined whether URHC exerted its function through miR-5007-3p in 7721 and Hep3B cells in EdU and colony formation assays. The proliferation of 7721 cells in the siRNA-URHC + miR-5007-3p inhibitor group was remarkably increased compared with that in the siRNA-URHC and siRNA-URHC significant + miR-5007-3p inhibitor NC groups, whereas HCC cell proliferation was evidently decreased.
in the over-URHC + miR-5007-3p mimic group compared with the over-URHC and over-URHC + miR-5007-3p mimic NC groups (Figures 4(a) and 4(b)). These results suggest that URHC function was reversed by transfection with miR-5007-3p inhibitor or mimic in 7721 and Hep3B cells.

3.5. URHC Regulates the Expression of DNAJB9 by Targeting miR-5007-3p in HCC Cells. It is well known that miRNAs play biological roles by targeting the 3′-UTR of target genes. The bioinformatics databases (miRDB, miRTarBase, and miRWalk) predicted that potential downstream genes of miR-5007-3p include BCOR, AJAP1, DNAJB9, RAI1, and others (Figures S2A and S2B). Among the targets of miR-5007-3p, we focused on DNAJB9, because the expression level of DNAJB9 was the highest in the HCC cells that highly expressed URHC (Figure S2C). We first measured the expression of DNAJB9 in HCC tissues, and its expression was found to be significantly increased (Figure 5(a)). In 7721 and 7402 cell lines, the mRNA level of DNAJB9 was significantly decreased in cells transfected with siRNA-URHC compared with control cells, whereas the expression of DNAJB9 in over-URHC cells showed the opposite result (Figure 5(b)).

| Name          | Accession | Query start | Query start | Subject start | Subject end | Score | Evalue |
|---------------|-----------|-------------|-------------|---------------|-------------|-------|--------|
| Has-miR-5007-3p | MIMAT0021036 | 74           | 91           | 4             | 21          | 72    | 1.5    |
| Has-miR-4698   | MIMAT0019793 | 59           | 73           | 2             | 16          | 66    | 4.7    |
| Has-miR-559    | MIMAT0003223 | 66           | 85           | 1             | 20          | 64    | 6.9    |
| Has-miR-3942-3p| MIMAT0019230 | 164          | 181          | 4             | 21          | 63    | 8.3    |

Figure 2: The subcellular location of URHC in HCC cell lines and tissues. (a) Detection of URHC by fluorescence in situ hybridization (FISH) in HCC cell lines 7721 and Hep3B. URHC: endogenous URHC; DAPI: DNA stained with DAPI; merge: merged images of DAPI and URHC immunofluorescence. Magnification: ×400. (b) FISH was performed to analyze URHC in HCC tissues and adjacent tissues. Magnification: ×400. (c) Cellular localization of URHC in 7721 and Hep3B cells is shown. GAPDH and U6 served as a cytoplasmic and nuclear localization marker, respectively. * P < 0.05.
Figure 3: Continued.
Many miRNAs have been shown to play a regulatory role in hepatocellular carcinoma (URHC), and our research group screened for a novel lncRNA. It is located on the forward strand of human chromosome 2:173958088–173958307, and its transcript length is 219 bp. The previous result shows that it was highly expressed in HCC cell lines, clinical HCC tissues, and poor survival in HCC patients, and URHC high expression promoted tumor growth and inhibited apoptosis via ERK/MAPK inactivation by targeting ZAK [33]. However, the precise regulatory mechanisms of URHC signaling in HCC are still largely unknown. In this study, we investigated the expression pattern of URHC in HCC. The results confirmed that URHC was preferentially localized in the cell cytoplasm, suggesting that it could function as a ceRNA to regulate the expression pattern and biological characteristics of miRNAs.

4. Discussion

In this study, we added the function of URHC in vivo and in vitro. URHC is predominantly in the cell cytoplasm and this indicates that URHC can function as a ceRNA to regulate the expression pattern and biological characteristics of miRNAs. Our study showed URHC high expression in HCC tissues and cell lines, while miR-5007-3p is low expression. In addition, miR-5007-3p can reverse the promoting effect of URHC on cell growth. However, URHC promotes cell proliferation of HCC and inhibitor miR-5007-3p is by regulation downstream DNAJB9. The study highlights the role of URHC in HCC and highlights URHC as a potential diagnostic and therapeutic target.

LncRNAs were upregulated in hepatocellular carcinoma (URHC), and our research group screened for a novel lncRNA. It is located on the forward strand of human chromosome 2:173958088–173958307, and its transcript length is 219 bp. The previous result shows that it was highly expressed in HCC cell lines, clinical HCC tissues, and poor survival in HCC patients, and URHC high expression promoted tumor growth and inhibited apoptosis via ERK/MAPK inactivation by targeting ZAK [33]. However, the precise regulatory mechanisms of URHC signaling in HCC are still largely unknown. In this study, we investigated the expression pattern of URHC in HCC. The results confirmed that URHC was preferentially localized in the cell cytoplasm, suggesting that it could function as a ceRNA to regulate the expression pattern and biological characteristics of miRNAs.

Many miRNAs have been shown to play a regulatory role in HCC, regulating the biological behavior of HCC cells, thereby affecting tumor progression. A study has shown that miR-5007-3p is expressed in the lymphatic metastasis tissue from gastric cancer patients via RT-qPCR. In addition, the results revealed that expressed of miR-5007-3p was upregulated...
Figure 4: miR-5007-3p reversed the promoting effect of URHC on the growth of HCC cells. (a, b) EdU and colony formation assays identified the phenomenon of URHC regulating each other to compete for the binding of miR-5007-3p in 7721 and Hep3B cell lines. Magnification: ×400.

Figure 5: Continued.
Figure 5: Continued.
in patients with positive lymphatic metastasis of primary gastric tumors [36]. In addition, another experiment by RT-qPCR indicated that the relative expression level of miR-5007-3p was significantly upregulated in the diabetic kidney disease group compared to type 2 diabetes group [37]. However, these researches did not examine miR-5007-3p specific cellular functions, and miR-5007-3p expression in HCC is unclear. Whether the important roles of URHC in HCC are associated with the dysregulation of miR-5007-3p also remains unknown. In our study, we found that the expression level of miR-5007-3p was the lowest in the URHC high expressing HCC cells and highest in the URHC-low expressing HCC cells, an inverse correlation between URHC and miR-5007-3p expression in HCC tissues and adjacent tissues was detected by qRT-PCR.

Whether the important roles of URHC in HCC are associated with the dysregulation of miR-5007-3p also remains unknown. In our study, we found that the expression level of miR-5007-3p was the lowest in the URHC high expressing HCC cells and highest in the URHC-low expressing HCC cells, an inverse correlation between URHC and miR-5007-3p expression in HCC tissues and adjacent tissues was detected by qRT-PCR. (b) RT-qPCR analysis of URHC-regulated DNAJB9 expression in 7721, 7402, 7404, and Hep3B cells. (c, d) The mRNA and protein levels of DNAJB9 in tumors were assessed. (e) The positive correlation between URHC and miR-5007-3p expression and the negative correlation between miR-5007-3p and DNAJB9 expression in HCC tissues are shown in scatter diagrams. (f) The predicted binding sites of miR-5007-3p in the DNAJB9 sequence are shown. (g) Luciferase reporter assay of 293T cells transfected with miR-5007-3p inhibitor/mimic or siRNA-URHC/over-URHC were analyzed by RT-qPCR and western blot. *P < 0.05, **P < 0.01, and ***P < 0.001.

**Data Availability**

The data used to support the findings of this study can be obtained from the corresponding author upon reasonable request. Additional supporting information may be found online in the Supplementary Materials section.

**Disclosure**

A preprint has previously been online but not published, which has been retracted [43].

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Authors’ Contributions**

Kunwei Niu, Shibin Qu, and Xuan Zhang contributed equally to this work.

**Acknowledgments**

This study was funded by the National Nature Science Foundation of China (Grant/Award nos. 81672716 and 81900571).

**Supplementary Materials**

Figure S1: RT-qPCR analysis for URHC-regulated miR-5007-3p, miR-559, miR-3942-3p, and miR-4986 expression in 7721, 7402, 7404, and Hep3B cells. *P < 0.05, **P < 0.01, and ***P < 0.001. Figure S2: (A, B) miRDB, miRTarBase,
References

[1] S. Xiao, M. Yang, H. Yang, R. Chang, F. Fang, and L. Yang, “miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling,” Oncogenesis, vol. 7, no. 11, Article ID 90, 2018.

[2] H. Li, M. Zhang, E. Linghu et al., “Epigenetic silencing of TMEM176A activates ERK signaling in human hepatocellular carcinoma,” Clinical Epigenetics, vol. 10, no. 1, Article ID 137, 2018.

[3] A. D. Chendid, P. W. Klein, M. F. Tiburi, M. M. Villwock, L. E. Bassani, and M. F. Chedido, “Sponndaneous rupture of hepatocellular carcinoma with haemopteritoneum: a rare condition in Western countries,” International Hepato-Pancreato-Biliary Association, vol. 3, no. 3, pp. 227–230, 2001.

[4] M. N. Protopapa, M. Lagadinou, T. Papagiannis, C. A. Gogos, and E. E. Solomou, “Hepatocellular carcinoma: an uncommon metastasis in the orbit,” Case reports in oncological medicine, vol. 2020, Article ID 7526042, 3 pages, 2020.

[5] S. Li, J. Yao, M. Xie, Y. Liu, and M. Zheng, “Exosomal miRNAs in hepatocellular carcinoma development and clinical responses,” Journal of Hematology & Oncology, vol. 11, no. 1, Article ID 54, 2018.

[6] J. Zhao, C. M. Greene, S. G. Gray, and M. W. Lawless, “Long noncoding RNAs in liver cancer: what we know in 2014,” Expert Opinion on Therapeutic Targets, vol. 18, no. 10, pp. 1207–1218, 2014.

[7] J. K. Di Stefano, “Long noncoding RNAs in the initiation, progression, and metastasis of hepatocellular carcinoma,” Non-coding RNA research, vol. 2, no. 3-4, pp. 129–136, 2017.

[8] J. H. He, Z. P. Han, J. M. Liu et al., “Overexpression of long non-coding RNA MEG3 inhibits proliferation of hepatocellular carcinoma HuH7 cells via negative modulation of miRNA-664,” Journal of Cellular Biochemistry, vol. 118, no. 11, pp. 3731–3721, 2017.

[9] J.-N. Xiao, T.-H. Yan, R.-M. Yu et al., “Long non-coding RNA UCA1 regulates the expression of Smad2 by miR-203 to promote hepatocellular carcinoma progression,” Journal of Cancer Research and Clinical Oncology, vol. 143, no. 6, pp. 981–990, 2017.

[10] Y. Wu, T. Yuan, W.-W. Wang et al., “Long noncoding RNA HOST2 promotes epithelial-mesenchymal transition, proliferation, invasion and migration of hepatocellular carcinoma cells by activating the JAK2-STAT3 signaling pathway,” Cellular Physiology and Biochemistry, vol. 51, no. 1, pp. 301–314, 2018.

[11] Y. Xu, X. Luo, W. He et al., “Long non-coding RNA PVTI/miR-150/HIG2 Axis regulates the proliferation, invasion and the balance of iron metabolism of hepatocellular carcinoma,” Cellular Physiology and Biochemistry, vol. 49, no. 4, pp. 1403–1419, 2018.

[12] J. Wang, X. Liu, H. Wu et al., “CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer,” Nucleic Acids Research, vol. 38, no. 16, pp. 5366–5383, 2010.

[13] Y.-N. Chang, K. Zhang, Z.-M. Hu et al., “Hypo-regulated lncRNAs in cancer,” Gene, vol. 575, no. 1, pp. 1–8, 2016.

[14] T. Li, X.-L. Meng, and W.-Q. Yang, “Long noncoding RNA PVT1 acts as a ‘sponge’ to inhibit microRNA-152 in gastric cancer cells,” Digestive Diseases and Sciences, vol. 62, no. 11, pp. 3021–3028, 2017.

[15] X. B. Guo, Z. Hua, C. Li et al., “Biological significance of long non-coding RNA FTX expression in human colorectal cancer,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 9, pp. 15591–15600, 2015.

[16] S. Hombach and M. Kretz, “Non-coding RNAs: classification, biology and functioning,” Advances in Experimental Medicine & Biology, vol. 937, pp. 3–17, 2016.

[17] C. P. Ponting, P. L. Oliver, and W. Reik, “Evolution and functions of long noncoding RNAs,” Cell, vol. 136, no. 4, pp. 629–641, 2009.

[18] Y. Fang and M. J. Fullwood, “Roles, functions, and mechanisms of long non-coding RNAs in cancer,” Genomics, Proteomics & Bioinformatics, vol. 14, no. 1, pp. 42–54, 2016.

[19] A. Bhan, M. Soleimani, and S. S. Mandal, “Long noncoding RNA and cancer: a new paradigm,” Cancer Research, vol. 77, no. 15, pp. 3965–3981, 2017.

[20] M. Quan, J. Chen, and D. Zhang, “Exploring the secrets of long noncoding RNAs,” International Journal of Molecular Sciences, vol. 16, no. 3, pp. 5467–5496, 2015.

[21] N. Dimitrova, J. R. Zamudio, R. M. Jong et al., “LincRNA-p21 activates p21 in cis to promote Polycym target gene expression and to enforce the G1/S checkpoint,” Molecular Cell, vol. 54, no. 5, pp. 777–790, 2014.

[22] L. Zhu, Y. Liu, Q. Chen et al., “Long-Noncoding RNA colorectal neoplasia differentially expressed gene as a potential target to upregulate the expression of IRX5 by miR-136-5P to promote oncogenic properties in hepatocellular carcinoma,” Cellular Physiology and Biochemistry, vol. 50, no. 6, pp. 2229–2248, 2018.

[23] G. Yang, X. Lu, and L. Yuan, “LncRNA: a link between RNA and cancer,” Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, vol. 1839, no. 11, pp. 1097–1109, 2014.

[24] F. P. Marchese, I. Raimondi, and M. Huarte, “The multidimensional mechanisms of long noncoding RNA function,” Genome Biology, vol. 18, no. 1, Article ID 206, 2017.

[25] E. A. Wentzel, C. L. Montgomery, H. W. Hwang et al., “Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model,” Cell, vol. 137, no. 6, pp. 1005–1017, 2009.

[26] M. Hatziapostolou, C. Polytarchou, E. Aggelidou et al., “An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis,” Cell, vol. 147, no. 6, pp. 1233–1247, 2011.

[27] B. Zheng, L. Liang, C. Wang et al., “MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer,” Clinical Cancer Research, vol. 17, no. 24, pp. 7574–7583, 2011.

[28] M. Mori, R. Triboulet, M. Mohseni et al., “Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer,” Cell, vol. 156, no. 5, pp. 893–906, 2014.

[29] J. G. Zhang, Y. Shi, D. F. Hong et al., “Corrigendum: miR-148b suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting WNT1/Fβ-catenin pathway,” Scientific Reports, vol. 7, Article ID 46886, 2017.
[30] X.-h. Liu, M. Sun, F.-q. Nie et al., "Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer," *Molecular Cancer*, vol. 13, no. 1, Article ID 92, 2014.

[31] J. Qu, M. Li, W. Zhong, and C. Hu, "Competing endogenous RNA in cancer: a new pattern of gene expression regulation," *International Journal of Clinical and Experimental Medicine*, vol. 8, no. 10, pp. 17110–17116, 2015.

[32] S. Wang, G. Gao, Y. He, Q. Li, Z. Li, and G. Tong, "Amidation-modified apelin-13 regulates PPARγ and perilipin to inhibit adipogenic differentiation and promote lipolysis," *Bioinorganic Chemistry and Applications*, vol. 2021, Article ID 3594630, 9 pages, 2021.

[33] W.-H. Xu, J.-B. Zhang, Z. Dang et al., "Long non-coding RNA URHC regulates cell proliferation and apoptosis via ZAK through the ERK/MAPK signaling pathway in hepatocellular carcinoma," *International Journal of Biological Sciences*, vol. 10, no. 7, pp. 664–676, 2014.

[34] K. A. Lennox and M. A. Behlke, "Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides," *Nucleic Acids Research*, vol. 44, no. 2, pp. 863–877, 2016.

[35] M. N. Cabili, M. C. Dunagin, P. D. McClanahan et al., "Localization and abundance analysis of human lncRNAs at single-cell and single-molecule resolution," *Genome Biology*, vol. 16, no. 1, Article ID 20, 2015.

[36] B. Yang, C. Jing, J. Wang et al., "Identification of microRNAs associated with lymphangiogenesis in human gastric cancer," *Clinical and Translational Oncology*, vol. 16, no. 4, pp. 374–379, 2014.

[37] Y. Zhao, A. Shen, F. Guo et al., "Urinary exosomal MiRNA-4534 as a novel diagnostic biomarker for diabetic kidney disease," *Frontiers in Endocrinology*, vol. 11, Article ID 590, 2020.

[38] H. J. Lee, J. M. Kim, K. H. Kim, J. I. Heo, S. J. Kwak, and J. A. Han, "Genotoxic stress/p53-induced DNAJB9 inhibits the pro-apoptotic function of p53," *Cell Death & Differentiation*, vol. 22, no. 1, pp. 86–95, 2015.

[39] J. Kurisu, A. Honma, H. Miyajima, S. Kondo, M. Okumura, and K. Imaizumi, "MDG1/ERdj4, an ER-resident DnaJ family member, suppresses cell death induced by ER stress," *Genes to Cells*, vol. 8, no. 2, pp. 189–202, 2003.

[40] Y. Huang, K. Arora, K. S. Mun et al., "Targeting DNAJB9, a novel ER luminal co-chaperone, to rescue ΔF508-CFTR," *Scientific Reports*, vol. 9, no. 1, Article ID 9808, 2019.

[41] F. Sun, Y. Liao, X. Qu et al., "Hepatic DNAJB9 drives anabolic biasing to reduce steatosis and obesity," *Cell Reports*, vol. 30, no. 6, pp. 1835–1847, 2020.

[42] N. K. Andeen, H.-Y. Yang, D.-F. Dai, M. J. MacCoss, and K. D. Smith, "DnaJ homolog subfamily B member 9 is a putative autoantigen in fibrillary GN," *Journal of the American Society of Nephrology*, vol. 29, no. 1, pp. 231–239, 2018.

[43] K. Niu, S. Qu, X. Zhang et al., "LncRNA-URHC functions as a ceRNA to regulate Danjb9 expression by competitively binding to miR-5007-3p in hepatocellular carcinoma," pp. 1–19, 2021.